Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: A meta-analysis

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 22, Issue 5, 2000, Pages 285-290

  Carvajal, A ^a   Garcia del Pozo, J ^a   Martin de Diego, I ^a   Rueda de Castro, A M ^a   Velasco, A ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Clinical trial; Dexfenfluramine; Fenfluramine; Meta analysis; Weight loss

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; HUMAN; META ANALYSIS; OBESITY; STATISTICAL ANALYSIS; WEIGHT REDUCTION;

EID: 0033847148     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2000.22.5.796647     Document Type: Article

References (38)

1. Drug treatment of obesity
2. Valvular heart disease associated with fenfluramine-phentermine
3. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
4. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
5. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
6. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine
7. International trial of long-term dexfenfluramine in obesity
8. Quantitative methods in the review of epidemiologic literature
9. A note on graphical presentation of estimated odds ratios from several clinical trials
10. Passive smoking and lung cancer: A publication bias?
11. Treatment of refractory obesity with fenfluramine
12. Anorectic effectiveness of differing dosage forms of fenfluramine
13. Double blind evaluation of reinforcing and anorectic actions of weight control medication
14. A double blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination
15. Dextrofenfluramine in the treatment of refractory obesity
16. Effects of fenfluramine in hypertriglyceridemic obese subjects
17. Efficacy and safety of dexfenfluramine in obese patients: A multi-center study
18. La Dexfenfluramina nel trattamento dell'obesita esogena
19. A six-month study of the effects of dexfenlfluramine on partially successful dieters
20. Positive effects of dexfenfluramine on energy expenditure during long term weight reduction in obese women
21. La dexfenfluramina nel trattamento dell'obesita. Studio multricentrico controllato vs placebo
22. Drug therapy after very-low-calorie-diets
23. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients
24. Dexfenfluramine in the treatment of severe obesity: A placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour
25. Effects of dexfenflufamine treatment on body weight and postpandrial thermogenesis in obese subjects. A double-blind placebo controlled study
26. Dexfenfluramine reduces cardiovascular risk factors
27. Prolonged surveillance of dexfenfluramine in severe obesity
28. Long term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine
29. Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet
30. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction
31. Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obesite individuals
32. Dexfenfluramine treatment of obesity: A double blind trial with post trial follow up
33. Effects of dexfenfluramine on weight loss and serum amino acids profile in obese subjects
34. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: Effects on body composition, nutrient intake and cardiovascular risk factors
35. Blinding, unblinding, and the placebo effect: An analysis of patients' guesses of treatment assignment in a double-blind clinical trial
36. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: A criteria-based meta-analysis
37. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities